Literature DB >> 2982999

Cytomegalovirus infection of human teratocarcinoma cells in culture.

E Gönczöl, P W Andrews, S A Plotkin.   

Abstract

Whereas human cytomegalovirus (HCMV) did not replicate in human embryonal carcinoma (EC) cells, it did replicate in some of the differentiated cells arising following the exposure of TERA-2-derived human EC cells to retinoic acid. On the other hand, retinoic acid did not induce a permissive state in several other diverse human cell lines, including an EC line, 2102Ep, which did not differentiate in response to this agent. Also, both TERA-2 and 2102Ep EC cells differentiated to a limited extent when grown at low cell density and a few of these cells became permissive for HCMV. Thus, susceptibility is the result of differentiation and not due to a direct effect of retinoic acid on viral replication. The nature of the block to HCMV replication in human EC cells is unknown, but viral DNA could be detected in the nucleus within an hour of infection and there was an increased anchorage-independent growth of undifferentiated and differentiated cells following HCMV infection. Viral replication is not subject to a general block in these cells, since another herpesvirus, herpes simplex virus type 1, replicated well.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982999     DOI: 10.1099/0022-1317-66-3-509

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

1.  Human cytomegalovirus infects Caco-2 intestinal epithelial cells basolaterally regardless of the differentiation state.

Authors:  A Esclatine; M Lemullois; A L Servin; A M Quero; M Geniteau-Legendre
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Immune responses to isolated human cytomegalovirus envelope proteins.

Authors:  E Gönczöl; F Hudecz; J Ianacone; B Dietzschold; S Starr; S A Plotkin
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

3.  The human cytomegalovirus major immediate-early distal enhancer region is required for efficient viral replication and immediate-early gene expression.

Authors:  J L Meier; J A Pruessner
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Reactivation of the human cytomegalovirus major immediate-early regulatory region and viral replication in embryonal NTera2 cells: role of trichostatin A, retinoic acid, and deletion of the 21-base-pair repeats and modulator.

Authors:  J L Meier
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Permissive cytomegalovirus infection of primary villous term and first trimester trophoblasts.

Authors:  D G Hemmings; R Kilani; C Nykiforuk; J Preiksaitis; L J Guilbert
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Nuclear localization of tegument-delivered pp71 in human cytomegalovirus-infected cells is facilitated by one or more factors present in terminally differentiated fibroblasts.

Authors:  Rhiannon R Penkert; Robert F Kalejta
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

7.  Constitutive and retinoic acid-inducible expression of cytomegalovirus immediate-early genes in human teratocarcinoma cells.

Authors:  R LaFemina; G S Hayward
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

8.  Latent infection of human ovarian teratocarcinoma cells with human cytomegalovirus. Brief report.

Authors:  S Kamiya; J Tanaka; T Ogura; H Sato; H Ogura; S Nakamura; M Hatano
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

9.  Susceptibility of mouse embryo to murine cytomegalovirus infection in early and mid-gestation stages.

Authors:  A Kashiwai; N Kawamura; C Kadota; Y Tsutsui
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Differentiation of human embryonal carcinoma cells induces human immunodeficiency virus permissiveness which is stimulated by human cytomegalovirus coinfection.

Authors:  G Hirka; K Prakash; H Kawashima; S A Plotkin; P W Andrews; E Gönczöl
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.